These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8414522

  • 1. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK, Nabissa PM, Reddy EP.
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [Abstract] [Full Text] [Related]

  • 2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 3. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS, Wu Y, McMahon R, Yu L, Rossi JJ, Forman SJ.
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [Abstract] [Full Text] [Related]

  • 4. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH, Wu SC, Chen WS, Yen CC, Yang MH, Tsai YC, Chen PM.
    Biochem Biophys Res Commun; 2004 Jun 04; 318(3):764-72. PubMed ID: 15144904
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec 04; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W.
    Klin Padiatr; 1995 Dec 04; 207(4):222-4. PubMed ID: 7564157
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL, Lewalle P, Martiat P.
    Stem Cells; 1993 Oct 04; 11 Suppl 3():89-95. PubMed ID: 8298481
    [Abstract] [Full Text] [Related]

  • 11. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P, Wright LA, Milliken S, Biggs JC.
    Exp Hematol; 1995 Aug 04; 23(9):986-9. PubMed ID: 7543419
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Aug 04; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 04; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 16. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z, Bakalova R, Ohba H, Ewis A, Ishikawa M, Shinohara Y, Baba Y.
    FEBS Lett; 2004 Jul 16; 570(1-3):195-204. PubMed ID: 15251464
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.